Corbus Pharmaceuticals Holdings, INC 8-K filings

Corbus Pharmaceuticals has appointed Winston Kung to its Board of Directors, effective August 16, 2024, following the resignation of Avery W. Catlin.

Corbus Pharmaceuticals provides an update on its diversified pipeline, including its next-generation Nectin-4 ADC, oral CB1R inverse agonist, and anti-v8 integrin mAb, with clinical data presented at ASCO 2024.

Corbus Pharmaceuticals announced positive clinical updates for its cancer drug CRB-701 and extended its cash runway through Q3 2027.

A Corbus Pharmaceuticals director, Yong Ben M.D., has adopted a Rule 10b5-1 plan to sell up to 10,607 shares of the company's common stock.

Corbus Pharmaceuticals' partner, CSPC Pharmaceutical Group, presented encouraging Phase 1 clinical trial data for SYS6002 (CRB-701), a next-generation Nectin-4 targeting antibody-drug conjugate, at the ASCO Annual Conference.

Corbus Pharmaceuticals' stockholders approved the 2024 Equity Compensation Plan at the annual meeting on May 16, 2024, which includes the reservation of 2,000,000 shares of common stock for issuance.

Corbus Pharmaceuticals has updated its risk factors, highlighting its complete dependence on third-party manufacturers and the potential risks associated with these relationships.

Corbus Pharmaceuticals announced positive first quarter 2024 financial results, highlighted by a significant capital raise and advancements in their clinical pipeline.

Corbus Pharmaceuticals has amended and restated the employment agreements for its CEO and CFO, effective April 10, 2024, extending their terms and outlining compensation and severance details.

Corbus Pharmaceuticals' CEO and CFO have adopted Rule 10b5-1 trading plans for the potential sale of company stock.

Corbus Pharmaceuticals announced encouraging clinical data for its oncology pipeline, including CRB-701, CRB-601, and CRB-913, and secured significant funding to extend its cash runway.

Corbus Pharmaceuticals Holdings, Inc. announces the resignation of its Chief Scientific Officer, Rachael Brake, Ph.D., effective February 19, 2024.

Corbus Pharmaceuticals is progressing its diversified pipeline, including a next-generation Nectin-4 ADC, an anti-integrin mAb, and a CB1R inverse agonist, with key clinical milestones expected in 2024.

Corbus Pharmaceuticals refiled an opinion related to a recent share offering to include a conformed signature that was initially omitted.

Corbus Pharmaceuticals has successfully priced a public offering of common stock, expected to generate approximately $88.5 million in net proceeds.

Corbus Pharmaceuticals has terminated its at-the-market offering prospectus supplement, halting immediate sales of common stock, but the underlying sales agreement remains active.

Corbus Pharmaceuticals reports preliminary financials for 2023, including approximately $20.9 million in cash, cash equivalents, and investments.

Corbus Pharmaceuticals' development partner, CSPC Pharmaceutical Group, presented encouraging Phase 1 clinical trial data for CRB-701 (SYS6002), a next-generation antibody-drug conjugate targeting nectin-4 positive tumors, at the 2024 ASCO Genitourinary Cancers Symposium.